Pipeline
CLINICAL STAGE ASSETS
Investigational immunotherapies targeting a range of types of cancers.
NEOANTIGEN-DIRECTED THERAPIES
From personalized to off-the-shelf our neoantigen-directed constructs are in leveraging advances in gene sequencing to pursue individualized approaches to cancer therapies.
ADXS-PSA
ADXS-PSA is under investigation for targeting the prostate-specific antigen (PSA) associated with prostate cancer and is in clinical development both as a monotherapy and in combination with immune checkpoint inhibitors for the treatments of metastatic castration-resistant prostate cancer (mCRPC).
Axalimogene Filolisbac
(AXAL)
Advaxis’ Lm Technology™ immunotherapy axalimogene filolisbac (AXAL) targets HPV-associated cancers.
SURVIVOR STORIES
Hear the personal stories of men and women who have fought cancer with axalimogene filolisbac in clinical trials.
Partnerships
Advaxis has embraced strategic collaborations with other major biopharmaceutical companies for the development and commercialization of some of its proprietary cancer immunotherapies. In addition, Advaxis is developing numerous distinct proprietary immunotherapies directly or in partnership with recognized cancer centers of excellence and with support from advocacy foundations.
PARTNERS
Advaxis has established clinical partners for its proprietary Lm Technology™ immunotherapies with numerous biopharmaceutical industry leaders.
LICENSING AGREEMENTS
Advaxis has exclusively licensed certain constructs of its Lm Technology™ proprietary immunotherapies to biopharmaceutical industry leaders for both human and animal therapeutics.
INSTITUTIONS AND FOUNDATIONS
Advaxis has also fostered strong relationships with the multiple academic institutions and foundations for the development of its clinical pipeline.